399 related articles for article (PubMed ID: 26939611)
1. Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study.
Dragovic G; Smith CJ; Jevtovic D; Dimitrijevic B; Kusic J; Youle M; Johnson MA
BMC Infect Dis; 2016 Mar; 16():106. PubMed ID: 26939611
[TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS mortality in a south east European country versus a west European country.
Dragovic G; Smith C; Jevtovic D; Kusic J; Salemovic D; Ranin J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19620. PubMed ID: 25394124
[TBL] [Abstract][Full Text] [Related]
3. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.
Panayidou K; Davies MA; Anderegg N; Egger M;
J Int AIDS Soc; 2018 Nov; 21(11):e25200. PubMed ID: 30614622
[TBL] [Abstract][Full Text] [Related]
4. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
5. [Choice of initial regimen for antiretroviral-naïve HIV patients: Analysis of motivation].
Rouveix E; Mortier E; Beauchet A; Dupont C; Gerbe J; Daneluzzi V; Brazille P; Berthe H; Zucman D; Genet P; Simonpoli AM; de Truchis P;
Rev Med Interne; 2016 Dec; 37(12):796-801. PubMed ID: 27372517
[TBL] [Abstract][Full Text] [Related]
6. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
7. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J; Moreno S; Bucher HC; Furrer H; Logan R; Sterne J; Pérez-Hoyos S; Jarrín I; Phillips A; Lodi S; van Sighem A; de Wolf W; Sabin C; Bansi L; Justice A; Goulet J; Miró JM; Ferrer E; Meyer L; Seng R; Toulomi G; Gargalianos P; Costagliola D; Abgrall S; Hernán MA;
Clin Infect Dis; 2012 May; 54(9):1364-72. PubMed ID: 22460971
[TBL] [Abstract][Full Text] [Related]
8. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
9. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
[TBL] [Abstract][Full Text] [Related]
11. Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK HIV clinic.
Dragovic GJ; Smith CJ; Jevtovic DJ; Johnson MA; Ranin J; Salemovic D; Youle MS
HIV Clin Trials; 2009; 10(5):306-13. PubMed ID: 19965332
[TBL] [Abstract][Full Text] [Related]
12. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
13. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
Cardoso SW; Luz PM; Velasque L; Torres TS; Tavares IC; Ribeiro SR; Moreira RI; Veloso VG; Moore RD; Grinsztejn B
BMC Infect Dis; 2014 Dec; 14():699. PubMed ID: 25523385
[TBL] [Abstract][Full Text] [Related]
15. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.
; Judd A; Chappell E; Turkova A; Le Coeur S; Noguera-Julian A; Goetghebuer T; Doerholt K; Galli L; Pajkrt D; Marques L; Collins IJ; Gibb DM; González Tome MI; Navarro M; Warszawski J; Königs C; Spoulou V; Prata F; Chiappini E; Naver L; Giaquinto C; Thorne C; Marczynska M; Okhonskaia L; Posfay-Barbe K; Ounchanum P; Techakunakorn P; Kiseleva G; Malyuta R; Volokha A; Ene L; Goodall R
PLoS Med; 2018 Jan; 15(1):e1002491. PubMed ID: 29381702
[TBL] [Abstract][Full Text] [Related]
16. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.
Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Liu CE; Lee YT; Tang HJ; Wang NC; Lin TY; Lee YC; Lin SP; Huang YS; Zhang JY; Ko WC; Cheng SH; Hung CC;
PLoS One; 2017; 12(6):e0179870. PubMed ID: 28665938
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia.
Kušić J; Mladenović M; Dimitrijević B; Aleksić B; Zec S; Jevtović D; Dragović Lukić G
J Virus Erad; 2016 Jan; 2(1):32-5. PubMed ID: 27482433
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
; Lanoy E; May M; Mocroft A; Phillip A; Justice A; Chêne G; Furrer H; Sterling T; Monforte AD; Force L; Gill J; Harris R; Hogg RS; Rockstroh J; Saag M; Khaykin P; de Wolf F; Sterne JA; Costagliola D
AIDS; 2009 Oct; 23(16):2199-208. PubMed ID: 19779320
[TBL] [Abstract][Full Text] [Related]
20. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
